A Phase 2 interventional study of Belumosudil in Psoriasis Vulgaris, sponsored by Kadmon Corporation, LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-03-23.
Sponsored by Kadmon Corporation, LLC (part of Sanofi) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.
Among the 764 studies in Psoriasis with a site in United States, this one is the 626th largest by enrollment of the 673 interventional ones that give a count, is one of 39 that started in 2014, is one of 200 in phase 2, and was the 304th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Modern Research Associates, PLLC · Sites in United States
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
InventisBio Co., Ltd · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
764 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 98 · Phase 2 218 · Phase 3 193 · Phase 4 117
First in 1977; this study’s year is marked. 39 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 77 across the 673 interventional studies, 200 across the 90 observational. Of the 645 that completed or were terminated, 375 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
524 of 764 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kadmon Corporation, LLC, one of the names counted as Sanofi. Under that name alone:
Kadmon Corporation, LLC is the lead sponsor of 20 studies on the registry; none are open to participants now.
Sanofi has 5 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
22 of the studies in Psoriasis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05981118Phase 3Wake Forest University Health SciencesComparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) | 2027-01 |
| NCT03987763Bausch Health Americas, Inc.A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis | 2026-11 |
| NCT05570955Wake Forest University Health SciencesDeucravacitinib Adherence Study | 2026-11 |
| NCT04036188Wright State UniversityTriamcinolone With Vitamin D Synergistic Efficacy in Psoriasis | 2026-12 |
| NCT07221890Brigham and Women's HospitalA Trial of Academic Detailing to Promote Prescribing of Biosimilars | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 764 studies in Psoriasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective is to assess the safety and tolerability of 200 mg of belumosudil administered orally once daily for 28 days.
This will be a Phase 2a, open-label, single-arm, safety and tolerability study of belumosudil given daily for treatment of psoriasis.
Eight subjects with moderately severe psoriasis who have failed at least 1 line of systemic therapy will be enrolled.
Treatment Period Eligible subjects who have failed at least 1 line of systemic therapy will be entered and treated for 4 weeks (28 days) with 200 mg of belumosudil given orally once daily (QD).
Subjects will undergo medical history evaluations, physical examinations, vital sign measurements, weight, adverse event assessments, concomitant medication assessments, and laboratory testing including but not limited to blood sample collection for hematology and chemistry, urinalysis, coagulation, lipid panel, electrocardiogram, pregnancy test for females of childbearing potential, testing with the Psoriasis Area and Severity Index (PASI) scale and Physician Global Assessment (PGA) scale, and pharmacokinetic sampling.
Follow-up Period:
Visit will occur 4 weeks after the last dose of study drug in the Treatment Period of the study. This visit must be done within ± 3 days of the scheduled visit. The same assessments will be performed as in the Treatment Period.
The duration of the study is 12 weeks: up to 4 weeks for screening, 4 weeks of treatment, and 4 weeks of follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Using any topical therapy except for the following:
History or presence of any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Belumosudil 200 mg (two 100 mg capsules) orally once daily for 28 days
Drug: Belumosudil
Also known as: Rezurock (brand name), KD025, SLx-2119
Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability
To evaluate the safety and tolerability of 200 mg of belumosudil administered PO QD to subjects for treatment of psoriasis
Time frame: Up to 12 weeks:Up to 4 weeks screening (depending on signed informed consent + 4 weeks treatment + 4 weeks follow-up
Efficacy: Change in Overall PASI (Psoriasis Area and Severity Index) From Baseline to Week 4 and Week 8
The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. The measures are the changes in PASI score at Week 4 from baseline and Week 8 from baseline. Negative changes are favorable; positive changes are unfavorable.
Time frame: 8 weeks: 4-week (28-day) treatment + 4-week (28-day) follow-up
Efficacy: Physician Global Assessment (PGA) at Week 4 and Week 8
PGA score after treatment with belumosudil 200 mg PO QD at 4 weeks (28 days treatment) and at 8 weeks (additional 4 weeks follow-up). Categories: 100% = clear; 75% to 99% clearing (Excellent) = marked improvement, nearly normal skin texture, some erythema may be present; 50% to 74% clear (Good) = moderate improvement, plaque has cleared to point of small scattered papules with normal intervening epidermis; 25% to 49% clearing (Fair) = slight improvement, decrease in scaling and softening of plaque; 0% to 24% clearing (Poor) = little or no change in scaling, erythema, or plaque elevation; Worse
Time frame: 8 weeks: 4-week (28-day) treatment + 4-week (28-day) follow-up
PK: Cmax and Cmin
Pharmacokinetic measures: Cmax = maximum observed plasma concentration; Cmin = minimum observed plasma concentration over 1 dosing period; KD025 = Parent Drug KD025; M1 = Metabolite KD025 M1; KD025 M2 = Metabolite M2. Day 1 Cmax: 8 subjects each in KD025 and M2, and 6 subjects in M1. Day 28 Cmax: 4 subjects each in KD025 and M2, and 1 subject in M1. Day 1 Cmin: 8 subjects each in KD025 and M2, and 3 subjects in M1. Day 28 Cmin: 4 subjects each in KD025 and M2, and 1 subject in M1.
Time frame: Measured at Baseline (Day 1) and Week 4 (28 days): predose (0), 1, 2, 4, 8, and 24 hours post-dose
PK: AUC(0-24) and AUC(Inf)
Pharmacokinetic measures: AUC(0-24) = area under concentration time-curve from pre-dose (time 0) to 24 hours post-dose; AUC(inf) = area under concentration time-curve extrapolated from Day 1 to infinity; KD025 = Parent Drug KD025; M1 = Metabolite KD025 M1; KD025 M2 = Metabolite M2.
Time frame: Measured at Baseline (Day 1) and Week 4 (28 days): predose (0), 1, 2, 4, 8, and 24 hours post-dose
PK: Tmax
Pharmacokinetic measure: Tmax = time of maximum observed plasma concentration. Day 1 Tmax: 7 subjects each in KD025 and M2, and 5 subjects in M1. Day 28 Tmax: 4 subjects each in KD025 and M2, and 1 subject in M1.
Time frame: Measured at Baseline (Day 1) and Week 4 (28 days): predose (0), 1, 2, 4, 8, and 24 hours post-dose
PK: t(1/2)
KD025 = Parent Drug KD025; KD025 M2 = Metabolite M2; t(1/2) = apparent terminal elimination half-life
Time frame: Measured at Baseline (Day 1) and Week 4 (28 days): predose (0), 1, 2, 4, 8, and 24 hours post-dose
Open-label, Phase 2a, single-arm study of subjects with moderately severe plaque psoriasis who had been stable for 6 months and had failed at least 1 line of systemic therapy. Subjects were recruited at 1 site in the U.S.
| Milestone | Belumosudil 200 mg PO QD |
|---|---|
| Started | 8 |
| Completed | 5 |
| Not completed | 3 |
| Withdrew: Adverse event | 2 |
| Withdrew: Protocol violation | 1 |
To evaluate the safety and tolerability of 200 mg of belumosudil administered PO QD to subjects for treatment of psoriasis
| Participants | Belumosudil 200 mg PO QD |
|---|---|
| All AEs | 4 |
| Related AEs | 1 |
| Grade ≥3 AEs | 1 |
| Grade ≥3 Related AEs | 0 |
| Grade 4 AEs | 0 |
| Deaths | 0 |
| SAEs | 1 |
| Related SAEs | 0 |
| AEs leading to discontinuation | 2 |
The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. The measures are the changes in PASI score at Week 4 from baseline and Week 8 from baseline. Negative changes are favorable; positive changes are unfavorable.
| Score on a scale | Belumosudil 200 mg PO QD |
|---|---|
| Baseline (Day 1) | 17.5 ± 8.41 |
| Week 4 (Day 28) | 16.3 ± 9.49 |
| Change from Baseline to Week 4 | -1.1 ± 3.04 |
| Week 8 (Day 56) | 14.7 ± 3.41 |
| Change from Baseline to Week 8 | 0.0 ± 1.54 |
PGA score after treatment with belumosudil 200 mg PO QD at 4 weeks (28 days treatment) and at 8 weeks (additional 4 weeks follow-up). Categories: 100% = clear; 75% to 99% clearing (Excellent) = marked improvement, nearly normal skin texture, some erythema may be present; 50% to 74% clear (Good) = moderate improvement, plaque has cleared to point of small scattered papules with normal intervening epidermis; 25% to 49% clearing (Fair) = slight improvement, decrease in scaling and softening of plaque; 0% to 24% clearing (Poor) = little or no change in scaling, erythema, or plaque elevation; Worse
| Participants | Belumosudil 200 mg PO QD |
|---|---|
| 4 weeks: 75% to 100% | 0 |
| 4 weeks: 50% to 74% clearing | 1 |
| 4 weeks: 25% to 49% clearing | 1 |
| 4 weeks: 0 to 24% clearing | 4 |
| 4 weeks: Worse | 2 |
| 8 weeks: 75% to 100% | 0 |
| 8 weeks: 50% to 74% clearing | 0 |
| 8 weeks: 25% to 49% clearing | 0 |
| 8 weeks: 0% to 24% clearing | 6 |
| 8 weeks: Worse | 1 |
| 8 weeks: Missing (no data) | 1 |
Pharmacokinetic measures: Cmax = maximum observed plasma concentration; Cmin = minimum observed plasma concentration over 1 dosing period; KD025 = Parent Drug KD025; M1 = Metabolite KD025 M1; KD025 M2 = Metabolite M2. Day 1 Cmax: 8 subjects each in KD025 and M2, and 6 subjects in M1. Day 28 Cmax: 4 subjects each in KD025 and M2, and 1 subject in M1. Day 1 Cmin: 8 subjects each in KD025 and M2, and 3 subjects in M1. Day 28 Cmin: 4 subjects each in KD025 and M2, and 1 subject in M1.
| ng/mL | Parent Drug KD025 | Metabolite M1 | Metabolite M2 |
|---|---|---|---|
| Cmax: Day 1 | 1240 ± 704 | 21.3 ± 10.9 | 221 ± 165 |
| Cmax: Day 28 | 810 ± 475 | 15.0 ± NA | 131 ± 152 |
| Cmin: Day 1 | 59.6 ± 29.3 | 18.7 ± 9.16 | 21.1 ± 6.13 |
| Cmin: Day 28 | 35.9 ± 22.9 | 10.7 ± NA | 17.6 ± 7.36 |
Pharmacokinetic measures: AUC(0-24) = area under concentration time-curve from pre-dose (time 0) to 24 hours post-dose; AUC(inf) = area under concentration time-curve extrapolated from Day 1 to infinity; KD025 = Parent Drug KD025; M1 = Metabolite KD025 M1; KD025 M2 = Metabolite M2.
| ng*hr/mL | Parent Drug KD025 | Metabolite M2 |
|---|---|---|
| AUC(0-24): Day 1 | 7360 ± 3180 | 1040 ± 545 |
| AUC(0-24): Day 28 | 5500 ± 3790 | 162 ± 2320 |
| AUC(inf) from Day 1 | 8230 ± 3600 | 1120 ± 680 |
Pharmacokinetic measure: Tmax = time of maximum observed plasma concentration. Day 1 Tmax: 7 subjects each in KD025 and M2, and 5 subjects in M1. Day 28 Tmax: 4 subjects each in KD025 and M2, and 1 subject in M1.
| hours | Parent Drug KD025 | Metabolite M1 | Metabolite M2 |
|---|---|---|---|
| Tmax: Day 1 | 2.00 (1.00 to 7.92) | 2.00 (1.00 to 2.00) | 2.00 (1.00 to 7.92) |
| Tmax: Day 28 | 4.00 (1.00 to 4.13) | 4.00 (4.00 to 4.00) | 4.00 (1.00 to 4.13) |
KD025 = Parent Drug KD025; KD025 M2 = Metabolite M2; t(1/2) = apparent terminal elimination half-life
| hours | Parent Drug KD025 | Metabolite M2 |
|---|---|---|
| t(1/2): Day 1 | 6.08 ± 0.681 | 4.25 ± 3.95 |
| t(1/2): Day 28 | 5.27 ± 0.692 | 2.26 ± NA |
Collected over 12 weeks: up to 4 weeks for screening, 4 weeks of treatment, and 4 weeks of follow-up.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Belumosudil 200 mg PO QD | 0/8 (0%) | 1/8 (12.5%) | 4/8 (50%) |
| Event | Belumosudil 200 mg PO QD |
|---|---|
| NauseaGastrointestinal disorders | 1/8 |
| VomitingGastrointestinal disorders | 1/8 |
| Anastomotic ulcerInjury, poisoning and procedural complications | 1/8 |
| NephrolithiasisRenal and urinary disorders | 1/8 |
| Event | Belumosudil 200 mg PO QD |
|---|---|
| Transaminase increasedInvestigations | 2/8 |
| NauseaGastrointestinal disorders | 1/8 |
| VomitingGastrointestinal disorders | 1/8 |
| Anastomotic ulderInjury, poisoning and procedural complications | 1/8 |
| NephrolithiasisRenal and urinary disorders | 1/8 |
| PyrexiaGeneral disorders | 1/8 |
| HypokalemiaMetabolism and nutrition disorders | 1/8 |
| Rib FractureInjury, poisoning and procedural complications | 1/8 |
| FallInjury, poisoning and procedural complications | 1/8 |
| SomnolenceNervous system disorders | 1/8 |
| Age, Continuous(years) | Belumosudil 200 mg PO QD |
|---|---|
| Mean | 47.6 ± 10.31 |
| Age, Customized(years) | Belumosudil 200 mg PO QD |
|---|---|
| Median | 49.5 (31 to 57) |
| Sex: Female, Male(Participants) | Belumosudil 200 mg PO QD |
|---|---|
| Female | 0 |
| Male | 8 |
| Race and Ethnicity Not Collected(Participants) | Belumosudil 200 mg PO QD |
|---|
| BMI(kg/m^2) | Belumosudil 200 mg PO QD |
|---|---|
| Mean | 29.42 ± 6.539 |
| BMI(kg/m^2) | Belumosudil 200 mg PO QD |
|---|---|
| Median | 27.61 (21.2 to 41.0) |
The record gives a start of Apr 2014, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2021, 7 years after primary completion. A results delay was requested in Oct 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belumosudil